Literature DB >> 3294290

Acquisition of Ig isotype diversity after bone marrow transplantation in adults. A recapitulation of normal B cell ontogeny.

A Velardi1, S Cucciaioni, A Terenzi, I Quinti, F Aversa, C E Grossi, F Grignani, M F Martelli.   

Abstract

To gain insight into the prolonged susceptibility to infections noted after allogeneic bone marrow transplantation (BMT), multiple parameters of the humoral immune system were serially monitored in ten bone marrow recipients. IgM B cells appeared in the circulation 2 to 4 mo after engraftment. During the first 6 mo, the IgM B cells expressed low levels of CD21 (C3d/EBV receptors) and were largely CD38+. IgG and IgA B cells were also found to coexpress surface IgM and IgD, indicating that they may be involved in a process of isotype switch. These features are characteristic of neonatal B cells. To explore the pattern of Ig isotype switch, the emergence of plasma cell precursors for each of the four IgG subclasses was examined by culturing blood lymphocytes with PWM or LPS and enumerating bone marrow plasma cells. A marked IgG2 and IgG4 plasma cell deficiency and a relative increase in IgG1 and IgG3 plasma cells were detected both in vitro and in vivo. Serum IgG2 and IgG4 levels were deficient for more than 18 mo after BMT, elevated IgG1 levels accounting for the normal or increased levels of total IgG. The data suggest that a selective unresponsiveness to polysaccharide Ag and IgG2 subclass deficiency may contribute to the late bacterial infections in BMT recipients. These features of gradual development of the humoral immune system in adults undergoing successful marrow engraftment reproduce some of the maturational steps that occur during normal B cell ontogeny over the first 1 to 2 yr of life.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3294290

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  Anti-CD20 monoclonal antibody therapy for autoimmune hemolytic anemia following T cell-depleted, haplo-identical stem cell transplantation.

Authors:  A Ship; W May; K Lucas
Journal:  Bone Marrow Transplant       Date:  2002-02       Impact factor: 5.483

2.  Antibacterial polysaccharide antibody deficiency after allogeneic bone marrow transplantation.

Authors:  I Quinti; A Velardi; S Le Moli; E Guerra; R D'Amelio; P Mastrantonio; M F Martelli; F Aiuti
Journal:  J Clin Immunol       Date:  1990-05       Impact factor: 8.317

Review 3.  Immune reconstitution following bone marrow transplantation.

Authors:  U N Verma; A Mazumder
Journal:  Cancer Immunol Immunother       Date:  1993-11       Impact factor: 6.968

4.  White pulp reconstitution after human bone marrow transplantation.

Authors:  A Nakayama; N Hirabayashi; M Ito; K Kasai; M Fujino; M Ohbayashi; J Asai
Journal:  Am J Pathol       Date:  1993-10       Impact factor: 4.307

Review 5.  Translational Mini-Review Series on B cell subsets in disease. Reconstitution after haematopoietic stem cell transplantation - revelation of B cell developmental pathways and lineage phenotypes.

Authors:  M Bemark; J Holmqvist; J Abrahamsson; K Mellgren
Journal:  Clin Exp Immunol       Date:  2012-01       Impact factor: 4.330

Review 6.  Immune reconstitution post allogeneic transplant and the impact of immune recovery on the risk of infection.

Authors:  Rohtesh S Mehta; Katayoun Rezvani
Journal:  Virulence       Date:  2016-07-06       Impact factor: 5.882

7.  Immunization with Haemophilus influenzae type b conjugate vaccine in children given bone marrow transplantation: comparison with healthy age-matched controls.

Authors:  M A Avanzini; A M Carrà; R Maccario; M Zecca; G Zecca; A Pession; P Comoli; M Bozzola; A Prete; R Esposito; F Bonetti; F Locatelli
Journal:  J Clin Immunol       Date:  1998-05       Impact factor: 8.317

8.  Pneumococcal immunity and response to immunization with pneumococcal vaccine in bone marrow transplant patients: the influence of graft versus host reaction.

Authors:  V Hammarström; K Pauksen; J Azinge; G Oberg; P Ljungman
Journal:  Support Care Cancer       Date:  1993-07       Impact factor: 3.603

9.  A preclinical acute GVHD mouse model based on chemotherapy conditioning and MHC-matched transplantation.

Authors:  K Riesner; M Kalupa; Y Shi; S Elezkurtaj; O Penack
Journal:  Bone Marrow Transplant       Date:  2015-11-23       Impact factor: 5.483

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.